Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Nightingale Health

2.08 EUR

+1.46 %

4,678 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
+1.46 %
+1.46 %
-6.31 %
-12.42 %
-16.97 %
-27.78 %
+104.72 %
-
-59.61 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
126.75M EUR
Turnover
82.1K EUR
P/E (adj.) (26e)
-7.64
EV/EBIT (adj.) (26e)
-5.14
P/B (26e)
2.41
EV/S (26e)
11.33
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
2.50 EUR
Updated
19.09.2025
Disclaimer
Antti Siltanen
Antti Luiro
Antti Luiro, Antti Siltanen
Show more
Latest research

Latest analysis report

Released: 19.09.2025

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.3
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Another welfare services country is piloting Nightingale's technology
Analyst Comment12/18/2025, 5:54 PM by
Antti Luiro, Antti Siltanen

Another welfare services country is piloting Nightingale's technology

The North Karelia wellbeing services county is piloting Nightingale's blood analysis technology.

Nightingale Health
Press release12/18/2025, 1:00 PM

North Karelia Wellbeing Services County adopts Nightingale Health’s disease risk assessment as part of public healthcare in Finland

Nightingale Health
New study on benefits of Nightingale blood test in identifying cardiovascular disease risk
Analyst Comment12/18/2025, 8:14 AM by
Antti Luiro, Antti Siltanen

New study on benefits of Nightingale blood test in identifying cardiovascular disease risk

A new study shows that the company's blood test can improve the detection of risk factors for heart attacks and strokes.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release12/17/2025, 7:30 AM

Landmark study: Nightingale Health’s blood test can improve prevention of heart attacks and strokes by 44% compared to current clinical practice

Nightingale Health
Life Science Companies as Investments | Life Science Night Dec. 9, 202514:40
Video12/16/2025, 7:30 AM

Life Science Companies as Investments | Life Science Night Dec. 9, 2025

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Changes in Nightingale’s management team continue
Analyst Comment12/15/2025, 7:59 AM by
Antti Luiro, Antti Siltanen

Changes in Nightingale’s management team continue

In light of the news, Nightingale is rebuilding its management team to better accelerate growth in its healthcare business.

Nightingale Health
Regulatory press release12/12/2025, 12:55 PM

Nightingale Health Plc restructures Management Team to accelerate healthcare business growth

Nightingale Health
Nightingale's CFO departs suddenly
Analyst Comment12/9/2025, 5:53 AM by
Antti Luiro, Antti Siltanen

Nightingale's CFO departs suddenly

The rapid change came as a surprise to us and appears to have occurred at the company's initiative, although the exact reasons remain unclear due to the concise announcement.

Nightingale Health
Regulatory press release12/8/2025, 8:35 AM

Change in Nightingale Health Plc’s Management Team

Nightingale Health
Nightingale expands its strategic partnership with Terveystalo
Analyst Comment11/27/2025, 9:12 AM by
Antti Luiro

Nightingale expands its strategic partnership with Terveystalo

With the new agreement, Nightingale's blood analysis technology will be made available to all Terveystalo customer groups, whereas previously it has mainly been used in health check-ups for occupational health customers.

Nightingale Health
Press release11/26/2025, 9:00 AM

Terveystalo and Nightingale Health deepen strategic partnership – preventive healthcare available to all Terveystalo customers in Finland

Nightingale Health
Press release11/20/2025, 8:00 AM

Nightingale Health enables access to world’s largest metabolomics dataset through UK Biobank collaboration

Nightingale Health
Regulatory press release11/6/2025, 3:10 PM

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Nightingale Health
Nightingale strengthens its research offering through strategic partnership
Analyst Comment11/5/2025, 2:59 PM by
Antti Luiro, Antti Siltanen

Nightingale strengthens its research offering through strategic partnership

Through this partnership, Nightingale will integrate Alamar's brain health proteomics technology into its multiomics offering.

Nightingale Health
Press release11/5/2025, 10:50 AM

Nightingale Health partners with Alamar Biosciences to expand its unique multiomics offering with ultra-sensitive proteomics for brain health

Nightingale Health
Regulatory press release10/2/2025, 12:30 PM

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health
Regulatory press release10/2/2025, 6:00 AM

Nightingale Health’s Annual Report for financial year 2024–2025 has been published

Nightingale Health
Nightingale’s service expands again with a new risk prediction
Analyst Comment9/26/2025, 7:16 AM by
Antti Luiro

Nightingale’s service expands again with a new risk prediction

Nightingale Health announced on Thursday the launch of a new risk detection tool that detects a high risk of dangerously high levels of lipoprotein (a), also known as Lp(a).

Nightingale Health
Press release9/25/2025, 9:10 AM

Breakthrough in cardiovascular disease risk assessment – Nightingale Health to offer Lp(a) risk detection as part of its routine health check

Nightingale Health
Nightingale 1-6'2025: Eyeing the next commercial breakthrough
Research9/19/2025, 11:29 AM by
Antti Luiro, Antti Siltanen

Nightingale 1-6'2025: Eyeing the next commercial breakthrough

In light of the earnings release, the company's high-potential international healthcare partnerships are progressing, even though the emergence of a commercial breakthrough is taking longer than we anticipated. However, the company's research segment has emerged as a near-term revenue growth driver, providing additional time to build stronger growth.

Nightingale Health
Forum discussions
I went to ask Teemu about news from the autumn and early winter on video Merry Christmas to the thread! Inderes Nightingale Health: Kaupalliset aihiot kehittyvät - Inderes Aika: 22.12.2025 klo 21.13 Videolla Nightingale Healthin toimitusjohtaja Teemu Suna käy läpi yhtiön syksyn kuulumisia...
12/22/2025, 7:53 PM
by Antti Luiro
19
Thanks for the interview. So it is progressing, but this certainly is a long game, as has been communicated. Now, with the goal for 2026 being a dozen commercial pilots, could 2027 be the year when we can expect a larger number of actual customer accounts to start? It was a bit of...
12/23/2025, 6:40 AM
by Puutaheinää
8
I don’t actually know anything; I’m only trying to discuss openly the research results that NG itself refers to. People here didn’t seem to know what NG’s own test ultimately costs the wellbeing services counties, let alone what the total cost is, because sampling costs and other...
12/19/2025, 1:55 PM
by Homeros
7
The Pathology Asia/Innoquest entity would certainly have been interesting, but it was left off the question list this time due to prioritization, and the chat ended up being quite long anyway. We’ll get an update on this with figures in connection with the H2 report however, I would...
1/2/2026, 7:04 AM
by Antti Luiro
5
@Antti_Luiro thanks for the interview. A nice extra episode. I listened to it again carefully and it started sounding a bit better than the first time. Lessons/Conclusions: Score2+ng cost is about 1.5x-2x (with volume pricing) compared to just Score2 (20-50e) → the financial benefit...
12/31/2025, 8:04 AM
by Cle
5
@Homeros This 2022 Nature article was not written by people working at NG. It was the 2023 Nature article. Additionally, it is sometimes forgotten in the discussion that a single test from NG does not measure the risk of developing one specific disease as an outcome, e.g., hypertension...
12/20/2025, 4:25 PM
by Monsieur
3
I’m clinging to this numerical “ten pilot cases during the spring” and the 50% revenue growth target like a drowning man to a stick, even though the former was stated as a rough estimate. It’s not just total fluff, though… We’ll see.
12/23/2025, 3:19 PM
by Cle
2
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.